All In Biotech

Drug Trial Radar · NCT06879067

Safety, Tolerability and Immune Effects of the Nasal Foralumab in Healthy Human Volunteers

A Phase I Study of the Safety, Tolerability and Immune Effects of the Nasal Anti-CD3 Monoclonal Antibody Foralumab in Healthy Human Volunteers

Last checked: Nov 19, 2026Latest source record: Mar 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

27

Actual

Start

Nov 12, 2018

Primary completion

Jul 23, 2019

Study completion Nov 9, 2020

Sponsor

Lead sponsor
Tiziana Life Sciences LTDIndustry
Sponsor type
Industry
First posted
Mar 17, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Triple (participant, care provider, investigator)
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The goal is to establish the safety of administration of nasal foralumab to healthy volunteers in escalating doses to determine the dose at which immune effects are observed. Patients will receive doses for 5 consecutive days and have a follow-up period.

Conditions

  • Safety
  • Tolerability

Interventions

  • PlaceboDrug

    Placebo nasal spray

  • Foralumab NasalDrug

    foralumab nasal spray

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety- Adverse EventsTime frame: Day 1 vs End of Study (Day 30)
  2. Immune EffectTime frame: Dat 1 vs End of Study (Day 30)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Ann Romney Center for Neurologic Diseases

    Boston, Massachusetts

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.